

## Xadago® Users Experience More “On” Time and Reduced Parkinson’s Disease Symptoms

The U.S. Food and Drug Administration approved Xadago® (safinamide) tablets as an add-on treatment for patients with Parkinson’s disease (PD) who are currently taking levodopa/carbidopa and experiencing “off” episodes (i.e., when a patient’s medications are not working well, causing an increase in PD symptoms, such as tremor and difficulty walking).

Efficacy of Xadago in treating PD was shown in a clinical trial of 645 participants who were also



© 2017 Shutterstock.com

taking levodopa and experiencing “off” time. Those receiving Xadago experienced more beneficial “on” time (i.e., when PD symptoms are reduced, without troublesome uncontrolled involuntary movement [dyskinesia]) compared to those receiving placebo. The increase in “on” time was accompanied by a reduction in “off” time and better

## Phase 1 Stem Cell Trial Successfully Completed for Alzheimer’s Disease Treatment

Longeveron announced the successful completion of enrollment in the first phase of its clinical research trial of Longeveron allogeneic human mesenchymal stem cells (LMSCs®) to treat Alzheimer’s disease.

Prior research shows that adult MSCs target and reduce inflammation, promote tissue repair, and improve brain function in mouse models of Alzheimer’s disease. Longeveron’s trial is the first U.S. clinical study of exogenously administered MSCs derived from the bone marrow of healthy adult donors for treating Alzheimer’s disease.

The company will review safety data prior to proceeding with the second phase: a 25-participant randomized, placebo-controlled, double-blind study evaluating the safety, tolerability, and efficacy of LMSCs in early-stage Alzheimer’s disease. The trial is taking place at the University of Miami’s Miller School of Medicine.

*Source. “Longeveron Achieves Milestone in Groundbreaking Stem Cell Trial for Alzheimer’s Disease.” (2017, March 15). Retrieved April 25, 2017, from <http://prm.to/2oHRmaz>.*



© 2017 Shutterstock.com

scores during “on” time than before treatment on a measure of motor function. These results were replicated in another clinical trial of 549 participants.

*Source. “FDA Approves Drug to Treat Parkinson’s Disease.” (2017, March 21). Retrieved April 25, 2017, from <http://prm.to/2mMYT6b>.*

*doi:10.3928/00989134-20170512-02*